Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
0(0%)
Results Posted
40%(6 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
2
13%
Ph phase_3
5
31%
Ph phase_4
1
6%

Phase Distribution

2

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 3Large-scale testing
5(62.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(15)
Terminated(1)

Detailed Status

Completed15
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 35 (62.5%)
Phase 41 (12.5%)

Trials by Status

completed1594%
terminated16%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_3

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

NCT01069900
completed

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

NCT00987792
completedphase_1

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

NCT01049022
completedphase_1

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

NCT01073891
terminatedphase_4

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

NCT00493038
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT01069900Phase 3

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Completed
NCT00987792

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Completed
NCT01049022Phase 1

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Completed
NCT01073891Phase 1

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Completed
NCT00493038Phase 4

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

Terminated
NCT00492726Phase 3

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

Completed
NCT00402727Phase 3

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

Completed
NCT00453349Phase 3

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Completed
NCT01434173

Risk of Acute Liver Injury in Users of Antimicrobials

Completed
NCT00879008

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Completed
NCT00492024Phase 3

BAY12-8039: 5 Days for Sinusitis vs Placebo

Completed
NCT01096511

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Completed
NCT00932802

Greatest International Antiinfective Trial With Avelox

Completed
NCT00997997

Avelox in Complicated Skin and Skin Structure Infections

Completed
NCT00876577

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

Completed
NCT00846911

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16